Business Context and Reporting Period
Company: vTv Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2019
Reporting Period: Specific event date of October 24, 2019.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt.
- Capital Raised: $2.0 million
- Shares Issued: 1,369,863 shares of Class A common stock
- Price Per Share: $1.46
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a purchase agreement under the terms of a September 26, 2019 Letter Agreement. The Company exercised its right to require the Investor to purchase the aforementioned shares. This transaction resulted in an immediate increase in cash liquidity of $2.0 million and an increase in outstanding Class A common stock.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction details are qualified by reference to the September 2019 Letter Agreement. No unusual items or contingencies are described in this specific report.
Investor Verification Checklist
- Verify the full terms of the September 26, 2019 Letter Agreement referenced in the filing.
- Confirm the dilution impact of the 1,369,863 newly issued shares on existing shareholders.
- Review the Company's subsequent Form 10-Q for the quarter ending September 30, 2019, where the Letter Agreement is filed as an exhibit.
- Assess the Company's cash runway post-transaction given the $2.0 million infusion.